Swiss Life Sciences Group has pioneered the development of Epinax™, a proprietary cannabidiol product which significantly reduces the effects of epilesy.

Epilepsy patients have only a few options to treat their condition, one of which is a specialist surgical procedure – the procedure has a high success rate but is not without risk to the patient – therefore only small number of patients are eligible for this type of surgery.